Squarepoint Ops LLC Takes $544,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Squarepoint Ops LLC acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 80,421 shares of the company's stock, valued at approximately $544,000.

Other institutional investors have also added to or reduced their stakes in the company. Softbank Group CORP. purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $99,152,000. Novo Holdings A S bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at $68,375,000. Vanguard Group Inc. grew its position in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares during the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth $23,429,000. Finally, Laurion Capital Management LP bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $16,611,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Trading Up 20.1%

RXRX traded up $0.92 on Friday, reaching $5.49. 59,957,988 shares of the company traded hands, compared to its average volume of 14,289,979. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The firm has a fifty day simple moving average of $4.81 and a two-hundred day simple moving average of $6.35. The company has a market cap of $2.23 billion, a P/E ratio of -3.59 and a beta of 0.84. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the prior year, the firm posted ($0.39) EPS. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RXRX. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.